Cerity Partners LLC raised its position in shares of CME Group Inc. (NASDAQ:CME - Free Report) by 60.0% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 72,917 shares of the financial services provider's stock after purchasing an additional 27,332 shares during the quarter. Cerity Partners LLC's holdings in CME Group were worth $16,089,000 at the end of the most recent reporting period.
Other large investors have also added to or reduced their stakes in the company. Y.D. More Investments Ltd purchased a new stake in CME Group in the second quarter valued at $36,000. McClarren Financial Advisors Inc. boosted its stake in shares of CME Group by 66.1% in the second quarter. McClarren Financial Advisors Inc. now owns 196 shares of the financial services provider's stock worth $39,000 after buying an additional 78 shares during the last quarter. Asset Dedication LLC grew its holdings in CME Group by 515.2% during the second quarter. Asset Dedication LLC now owns 203 shares of the financial services provider's stock worth $40,000 after acquiring an additional 170 shares during the period. Thurston Springer Miller Herd & Titak Inc. raised its position in CME Group by 62.2% during the third quarter. Thurston Springer Miller Herd & Titak Inc. now owns 193 shares of the financial services provider's stock valued at $43,000 after acquiring an additional 74 shares in the last quarter. Finally, Bank & Trust Co purchased a new position in CME Group during the second quarter valued at approximately $76,000. Hedge funds and other institutional investors own 87.75% of the company's stock.
Insider Transactions at CME Group
In related news, CFO Lynne Fitzpatrick sold 754 shares of the firm's stock in a transaction that occurred on Sunday, September 15th. The shares were sold at an average price of $216.99, for a total value of $163,610.46. Following the sale, the chief financial officer now owns 13,261 shares of the company's stock, valued at $2,877,504.39. This trade represents a 5.38 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Bryan T. Durkin sold 7,593 shares of CME Group stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $214.59, for a total transaction of $1,629,381.87. Following the completion of the transaction, the director now owns 55,607 shares of the company's stock, valued at $11,932,706.13. This represents a 12.01 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 15,621 shares of company stock valued at $3,441,063. 0.30% of the stock is currently owned by corporate insiders.
Analyst Ratings Changes
Several equities analysts have recently weighed in on the stock. Morgan Stanley lifted their target price on shares of CME Group from $210.00 to $233.00 and gave the company an "equal weight" rating in a report on Thursday, October 17th. Royal Bank of Canada reiterated a "sector perform" rating and issued a $235.00 target price on shares of CME Group in a research report on Thursday, October 24th. Piper Sandler raised their price target on shares of CME Group from $240.00 to $250.00 and gave the company an "overweight" rating in a research note on Monday, October 28th. Redburn Atlantic lowered CME Group from a "buy" rating to a "neutral" rating and set a $244.00 price target on the stock. in a research note on Tuesday, October 8th. Finally, Deutsche Bank Aktiengesellschaft decreased their price objective on CME Group from $227.00 to $226.00 and set a "hold" rating on the stock in a report on Monday, November 11th. Four equities research analysts have rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, CME Group presently has an average rating of "Hold" and an average price target of $224.47.
Get Our Latest Analysis on CME Group
CME Group Trading Up 1.4 %
NASDAQ CME traded up $3.32 during trading hours on Tuesday, reaching $232.69. The company had a trading volume of 1,468,747 shares, compared to its average volume of 1,921,060. CME Group Inc. has a 1-year low of $190.70 and a 1-year high of $232.69. The stock has a market capitalization of $83.85 billion, a P/E ratio of 24.12, a price-to-earnings-growth ratio of 5.28 and a beta of 0.55. The stock has a 50-day moving average of $223.86 and a 200 day moving average of $211.19. The company has a current ratio of 1.02, a quick ratio of 1.02 and a debt-to-equity ratio of 0.09.
CME Group (NASDAQ:CME - Get Free Report) last announced its earnings results on Wednesday, October 23rd. The financial services provider reported $2.68 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.65 by $0.03. CME Group had a return on equity of 13.39% and a net margin of 57.34%. The company had revenue of $1.58 billion for the quarter, compared to analyst estimates of $1.59 billion. During the same quarter in the previous year, the company earned $2.25 earnings per share. The firm's quarterly revenue was up 18.4% compared to the same quarter last year. As a group, research analysts anticipate that CME Group Inc. will post 10.22 earnings per share for the current fiscal year.
CME Group Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, December 27th. Shareholders of record on Monday, December 9th will be given a $1.15 dividend. This represents a $4.60 annualized dividend and a yield of 1.98%. The ex-dividend date of this dividend is Monday, December 9th. CME Group's dividend payout ratio is currently 48.37%.
CME Group Company Profile
(
Free Report)
CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.
Featured Articles
Before you consider CME Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CME Group wasn't on the list.
While CME Group currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.